Atea completes enrollment of 880+ patients across 17 countries in Phase 3 HCV trial
AVIR•Atea Pharmaceuticals enrolled over 880 HCV treatment-naïve patients across 120 sites in 17 countries for its global Phase 3 C-FORWARD trial comparing bemnifosbuvir plus ruzasvir to sofosbuvir-velpatasvir. Topline results are expected around year-end 2026 with North American readout from C-BEYOND slated mid-2026.
1. Completion of Global Enrollment
Atea Pharmaceuticals has wrapped enrollment in its Phase 3 C-FORWARD trial with more than 880 HCV treatment-naïve patients across roughly 120 clinical sites in 17 countries outside North America.
2. Head-to-Head Comparison with Standard of Care
The open-label trial pits the eight- to twelve-week regimen of bemnifosbuvir plus ruzasvir against the standard 12-week fixed dose of sofosbuvir-velpatasvir, enrolling patients with and without compensated cirrhosis and diverse HCV genotypes for a broad label potential.
3. Upcoming Topline Results and Next Steps
Topline efficacy and safety data from C-FORWARD are anticipated around year-end 2026, while the North American C-BEYOND trial is on track to report mid-2026, advancing Atea toward potential regulatory filings.
